Improve your clinical cancer research—and the potential impact of your work
Cutting-edge clinical cancer research solutions from Illumina deliver the accurate information your lab needs to improve the quality of your reporting and optimize care. Rapidly analyze expert-defined genes and mutation hotspots to find actionable variants in any type of cancer, including solid tumors and hematological malignancies.
Our workflow solutions for translational cancer research include both fixed and customizable cancer panels and a comprehensive range of systems that can be scaled to meet your needs. Our multi-analyte approach enables you to get thorough information efficiently and cost-effectively, even from small specimens. In addition, these integrated solutions include data analysis and reporting capabilities to help you communicate significant findings effectively.
Achieve Comprehensive NTRK Fusion Screening
In this webinar, learn about a hybrid-capture next-generation sequencing (NGS) assay that queries RNA and is able to detect all NTRK fusions, agnostic of fusion partners.
Clinical Cancer Research Methods
See how the latest advances in genomic technologies can help to identify important mutations in cancer.
- Somatic Mutations
- Germline Mutations
- Comprehensive Genomic Profiling
- Cancer Cytogenetics
- Products
Somatic Mutations
Molecular profiling is critical for characterizing somatic mutations in cancer and can help to identify important biomarkers. Next-generation sequencing (NGS) is becoming more widely adopted as a valuable method for detecting somatic mutations in cancer.
Germline Mutations
Germline mutations that predispose individuals to cancer can be detected through various approaches, from genome-wide association studies to whole-genome and targeted sequencing.
Comprehensive Genomic Profiling
This NGS approach consolidates hundreds of cancer-related markers, including different variant types, into a single assay.
Cancer Cytogenetics
Using cytogenomic analysis to understand the role chromosomal aberrations play in cancer is an integral part of current genomic medicine. Microarrays and NGS enable a complete view of chromosomal aberrations in cancer.
Products
Illumina offers various products to support clinical cancer research. Our products feature integrated workflows that are easy to implement in standard lab procedures and simple analysis and reporting capabilities.
TruSight Oncology 500
TruSight Oncology 500 is a next-generation sequencing (NGS) tumor profiling assay that analyzes hundreds of cancer-related biomarkers. It supports identification of all relevant DNA and RNA variants implicated in various tumor types.
Learn More
RET Alterations in Non-Small Cell Lung Cancer
Jaclyn Hechtman, MD, Associate Attending Pathologist at Memorial Sloan Kettering Cancer Center, discusses the relevance of RET alterations in non-small cell lung cancer and the pros and cons of different technical approaches to identify RET fusions and single-nucleotide variants.
View Webinar
Featured Clinical Cancer Research Articles
Accurate Identification of Cancer Biomarkers Paves the Way for Personalized Medicine
An NGS panel enables translational cancer researchers to seek answers to multiple questions in one assay.
Read Interview
The Changing Landscape of NGS Implementation in Molecular Diagnostic Laboratories
Key opinion leaders discuss the ongoing challenges and potential of NGS in oncology testing.
Read Interview
TruSight Oncology Family Grows with Liquid Biopsy and High-Throughput Assays
The latest additions to the Illumina portfolio of comprehensive cancer profiling assays provide labs with the flexibility to run tissue or blood plasma samples on a single high-throughput platform.
Read ArticleAdvancing Clinical Cancer Research with NGS
Dr Rossi highlights the value of NGS for oncology, including the cost-effective analysis of multiple genes in a single test.
View Video
Targeted Power for Clinical Cancer Research
The MiniSeq System delivers cost-efficient, reliable sequencing for low-throughput clinical cancer research labs. Perform accurate profiling of solid tumors, hematological cancers, and germline mutations on your benchtop.
View System
Featured Clinical Cancer Research Workflow
Library Prep
AmpliSeq for Illumina Focus Panel
Optimized for clinical cancer research applications and available as predesigned or made-to-order panels; use with targets ranging from a few to hundreds of genes in a single run.
Compare Targeted Cancer Research PanelsSequencing
MiniSeq System
NGS that fits your benchtop and your budget. Perform accurate tumor profiling in your own lab, on your own schedule.
View All Benchtop SequencersData Analysis
Local Run Manager
Multifunctional, integrated MiniSeq software performs automatic onboard data analysis.
Find BaseSpace Apps for NGS Data AnalysisLearn More
Accurate Gene Fusion Detection in Sarcomas
With NGS, you can easily survey hundreds of genes to detect known and novel fusion partners and characterize sarcoma subtypes.
NGS in Pathology Labs
Dr Rachel Butler discusses why their lab adopted NGS and explains its advantages in molecular pathology for profiling solid tumor samples.
Interested in receiving newsletters, case studies, and information on cancer genomics?
サインアップ
Introduction to NGS for Pathologists
Visit our Medical Genetics website to download an introduction to NGS technology and applications for molecular pathologists.
NGS for FFPE Tumor Specimens
Dr Rossi explains the value of molecular testing, and helps newcomers to NGS explore targeted sequencing applications.
Advancing Pathology with NGS
Dr Jaime Platt provides insights into the potential of NGS integration into clinical research, with case examples of deep sequencing in tumor samples.
Reimbursement Environment for NGS
Charles Mathews of Boston Healthcare discusses the reimbursement environment for next-generation sequencing.
Multi-Site Validation of Solid Tumor Panel
A study across seven different labs in Europe demonstrates the robustness of the TruSight Tumor 15 panel.
